LAKE FOREST, Ill. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its preliminary financial results for the second quarter of 2019. Second Quarter 2019 and Recent Business Highlights Net revenue was $178 million ,

LAKE FOREST, Ill. , July 11, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before market open on Thursday, August 1, 2019 outlining its second quarter 2019 financial results.

LAKE FOREST, Ill. , June 28, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched its first-to-market generic of Loteprednol Etabonate Ophthalmic Suspension, 0.5%.

LAKE FOREST, Ill. , June 25, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a warning letter from the U.S. Food and Drug Administration ( FDA ) related to the inspection of its Somerset, New Jersey manufacturing

LAKE FOREST, Ill. , May 30, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 9:30 a.m. EDT in New York, NY .

LAKE FOREST, Ill. , May 20, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration ( FDA ) for Azelastine

LAKE FOREST, Ill. , May 20, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the 2019 RBC Capital Markets Healthcare Conference on Wednesday, May 22, 2019 at 2:05 p.m. EDT in New York, NY .

-Operational improvements drive sequential growth- -Full year outlook anticipates further sequential growth throughout the year- LAKE FOREST, Ill. , May 07, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced

LAKE FOREST, Ill. , April 18, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration ( FDA ) for Loteprednol

LAKE FOREST, Ill. , April 18, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration ( FDA ) for Fluticasone

LAKE FOREST, Ill. , April 15, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before market open on Tuesday, May 7, 2019 outlining its first quarter 2019 financial results.

LAKE FOREST, Ill. , March 21, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (NASDAQ: AKRX), today announced that Dandy Dorado-Boladeres has been named as Executive Vice President of Global Quality, effective March 25, 2019. Mr. Dorado brings decades of pharmaceutical industry experience and expertise with

LAKE FOREST, Ill. , March 01, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX) announced today that the Delaware Court of Chancery has denied a request by Fresenius Kabi AG to bring a fraud claim against Akorn.   On February 20 , Fresenius filed a proposed amended counterclaim seeking to add a

LAKE FOREST, Ill. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its financial results for the year ended 2018. Fourth Quarter 2018 and Recent Business Highlights Net revenue was $153 million , a decline of $33

LAKE FOREST, Ill. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX) today announced that it strongly contests Fresenius’ proposed amended claims filed earlier today. Akorn believes these claims are meritless and overreaching. Akorn denies the allegations and will vigorously defend

LAKE FOREST, Ill. , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Thursday, February 28, 2019 outlining the fourth quarter and full year 2018 results.

LAKE FOREST, Ill. , Jan. 28, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), today announced that it has appointed a new executive team member and two new board members. Christopher C. Young joins Akorn as Executive Vice President, Global Operations reporting to Douglas Boothe , President &

LAKE FOREST, Ill. , Jan. 09, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a warning letter, dated January 4 , from the U.S. Food and Drug Administration ( FDA ) related to an inspection of its Decatur, Illinois

LAKE FOREST, Ill. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (NASDAQ: AKRX), today announced that Akorn granted an inducement equity award in accordance with Nasdaq Listing Rule 5635(c)(4) pursuant to an employment arrangement with Akorn’s newly appointed President and Chief Executive Officer